Evidence map›Paper›PMID 29473907›Full record

ArticleViruses2018

Pharmacological Inhibition of Protein Kinase C Reduces West Nile Virus Replication.

Ana B Blázquez, Ángela Vázquez-Calvo, Miguel A Martín-Acebes, Juan-Carlos Saiz

Open access · goldAbstract read
In one paragraph

Article in Viruses, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
4.8field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 30 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Review
  7. Review
  8. Article
  9. Article
  10. Article
  11. Potential for Protein Kinase Pharmacological Regulation inInternational journal of molecular sciences · 2020
    Review
  12. Host-Directed Antiviral Therapy.Clinical microbiology reviews · 2020
    Review
  13. Article
  14. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Ana B BlázquezDepartment of Biotechnology, INIA, Ctra. Coruña Km. 7.5, 28040 Madrid, Spain. blazquez@inia.es.ORCID 0000-0002-0847-0977
Ángela Vázquez-CalvoDepartment of Biotechnology, INIA, Ctra. Coruña Km. 7.5, 28040 Madrid, Spain. angelavazquezcalvo@gmail.com.
Miguel A Martín-AcebesDepartment of Biotechnology, INIA, Ctra. Coruña Km. 7.5, 28040 Madrid, Spain. martin.mangel@inia.es.ORCID 0000-0001-6015-3613
Juan-Carlos SaizDepartment of Biotechnology, INIA, Ctra. Coruña Km. 7.5, 28040 Madrid, Spain. jcsaiz@inia.es.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Flaviviruses are relevant animal and human pathogens that include West Nile virus (WNV), Japanese encephalitis virus, dengue virus, or Zika virus, among others. Currently, no licensed therapy is available to fight flaviviral infections. Protein kinases C (PKCs) constitute a family of multifunctional lipid-dependent isoenzymes that regulate a wide variety of cellular processes (apoptosis, differentiation, proliferation, cellular transformation, motility, adhesion, etc.) being currently considered at the front line of drug development for the treatment of diverse human disorders. PKCs have also been implicated in different steps during viral replication; however, nowadays, results regarding their role in flavivirus replication are controversial. Here we demonstrate that calphostin C and chelerythrine, two broad-PKC inhibitors that target conventional, novel and atypical PKCs, significantly inhibit WNV multiplication in cell culture without affecting cell viability. A reduction of viral yields was observed in treated cells when compared with mock-treated cells. Likewise, immunofluorescence detection of viral enveloped E protein was reduced in treated cells, as was the amount of viral RNA released to the supernatant, mainly in those treated with chelerythrine. On the other hand, two PKC inhibitors specific for conventional and novel isoforms (staurosporine and enzastaurine) did not show any significant effect in WNV multiplication. These results suggested that PKCs, more probably atypical PKCs, are likely involved in WNV multiplication, although both broad-spectrum tested drugs seem to act through different mechanisms, and point to them as potential antiviral candidates for WNV, as well as for other related flaviviruses.

Indexed as

AnimalsAntiviral AgentsChlorocebus aethiopsEnzyme InhibitorsHumansProtein Kinase CVero CellsVirus ReplicationWest Nile FeverWest Nile virusAntiviral AgentsEnzyme InhibitorsProtein Kinase Cprotein kinase Cviral replicationWest Nile virus

Identifiers

PMID29473907
PMCPMC5850398
OpenAlexW2789963447

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.